The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52

Scienmag

OCTOBER 7, 2020

Computational algorithms enable identification and optimization of RNA-based tools for myriad applications DNA and RNA have been compared to “instruction manuals” containing the information needed for living “machines” to operate.

RNA 69

RNA DNA Containment Bioinformatics 69

Scienmag

APRIL 8, 2021

Many tumours have a higher number of mutations due to a antiviral defence mechanism, the APOBEC system, which can accidentally damage DNA and cause mutations. Credit: IRB Barcelona In cancer, personalised medicine takes advantage of the unique genetic changes in an individual tumour to find its vulnerabilities and fight it.

Scientist 53

Scientist DNA Genetics Medicine 53

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Rapid and accurate DNA synthesis .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

JULY 26, 2023

This leap in understanding, which has been facilitated by the emergence of next generation sequencing (NGS) technologies and bioinformatics tools such as artificial intelligence (AI), has brought forward a new wave of precision medicine resources, diagnostics, and therapeutics specifically aiming to leverage the microbiome.

Medicine 52

Medicine Genome Genomics Bioinformatics 52

XTalks

DECEMBER 13, 2023

This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

NOVEMBER 30, 2023

Sphere Fluidics presence on the exhibition floor was bolstered by a presentation from Richard Hammond: ‘Picodroplets for cell Line engineering: A novel automation approach’. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

SEPTEMBER 7, 2022

Many companies have embarked on a digitalisation journey, convinced that their notebook entries, DNA and protein designs, samples used in experiments, and experimental conditions should all be tracked and stored in software. If all the work scientists do is captured in software, it ought to be easier to analyse. .

Scientist 52

Scientist Life Science Antibody Protein 52